The results of this study provide valuable evidence for policymakers and healthcare providers in LMICs who are increasingly incorporating GLP-1 receptor agonists and SGLT-2 inhibitors into diabetes management protocols. This evidence concerns the gene SLC5A2 and diabetes mellitus.